Hudson Canyon Capital Management Biogen Inc. Transaction History

Hudson Canyon Capital Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$190.52 - $236.72 $61,919 - $76,934	325 Added 4.22%	8,025 $1.86 Billion
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $730,770 - $824,792	2,885 Added 59.92%	7,700 $1.98 Billion
Q2 2023 Aug 02, 2023	SELL	$275.25 - $318.06 $42,113 - $48,663	-153 Reduced 3.08%	4,815 $1.37 Billion
Q1 2023 Aug 02, 2023	BUY	$256.56 - $292.34 $248,350 - $282,985	968 Added 24.2%	4,968 $1.38 Billion
Q4 2022 Aug 02, 2023	BUY	$252.44 - $306.72 $315,550 - $383,400	1,250 Added 45.45%	4,000 $1.11 Billion
Q3 2022 Aug 02, 2023	BUY	$194.69 - $268.46 $535,397 - $738,265	2,750 New	2,750 $734 Million
Q2 2022 Aug 02, 2023	SELL	$187.54 - $223.02 $1.13 Million - $1.34 Million	-6,027 Closed	0 $0
Q4 2021 Aug 02, 2023	SELL	$223.92 - $287.77 $66,728 - $85,755	-298 Reduced 4.71%	6,027 $1.45 Billion
Q2 2021 Aug 02, 2023	SELL	$259.0 - $414.71 $6,475 - $10,367	-25 Reduced 0.39%	6,325 $2.19 Billion
Q1 2021 Aug 02, 2023	BUY	$242.95 - $284.63 $128,034 - $150,000	527 Added 9.05%	6,350 $1.78 Billion
Q4 2020 Aug 02, 2023	BUY	$236.26 - $355.63 $1.38 Million - $2.07 Million	5,823 New	5,823 $1.43 Billion

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Hudson Canyon Capital Management, based on Form 13F filings with the SEC.

Stay updated on Hudson Canyon Capital Management with notifications on news.